Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors by Balak Marissa N, Gong Yixuan, Riely Gregory J, Somwar Romel, Li Allan R, Zakowski Maureen F, Chiang Anne, Yang Guangli, Ouerfelli Ouathek, Kris Mark G, Ladanyi Marc, Miller Vincent A, Pao William in Clinical cancer research : an official journal of the American Association for Cancer Research (2006).

[PMID: 17085664] PubMed


In patients whose lung adenocarcinomas harbor epidermal growth factor receptor (EGFR) tyrosine kinase domain mutations, acquired resistance to the tyrosine kinase inhibitors (TKI) gefitinib (Iressa) and erlotinib (Tarceva) has been associated with a second-site EGFR mutation, which leads to substitution of methionine for threonine at position 790 (T790M). We aimed to elucidate the frequency and nature of secondary EGFR mutations in patients with acquired resistance to TKI monotherapy.

[ hide abstract ]

Discussed In Paper


Variant Annotations

Sign in to see variant annotations.

Rx Annotations

No dosing information annotated.